MPM Oncology Impact Management »

Monte Rosa Therapeutics shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Monte Rosa Therapeutics (GLUE) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Monte Rosa Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Monte Rosa Therapeutics held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Monte Rosa Therapeutics by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2025-12-31 $18M 1.2M 15.68

More positions owned by MPM Oncology Impact Management

Cullinan Therapeutics Common (CGEM)
Madrigal Pharmaceuticals Common (MDGL)
Liquidia Corp Common (LQDA)
Trevi Therapeutics Common (TRVI)
Edgewise Therapeutics Common (EWTX)
Revolution Medicines Common (RVMD)
Agios Pharmaceuticals Common (AGIO)
Uniqure NV Common (QURE)
PTC Therapeutics Common (PTCT)
Syndax Pharmaceuticals Common (SNDX)
Dyne Therapeutics Common (DYN)
Tarsus Pharmaceuticals Common (TARS)
Stoke Therapeutics Common (STOK)
Alumis Common (ALMS)
Urogen Pharma Common (URGN)

View all positions for MPM Oncology Impact Management

Top funds holding Monte Rosa Therapeutics

NEA Management Company
BVF
Baker Bros. Advisors
TCG Crossover Management
Versant Venture Management
BlackRock
Suvretta Capital Management
Vanguard Group
FMR
State Street Corporation
Aisling Capital Management
Alphabet
American Century Companies
Geode Capital Management
MPM Oncology Impact Management

View all funds holding Monte Rosa Therapeutics